

Anti-CD14 Treatment With IC14 in Hospitalized ARDS Patients

NCT06513949

Status	RECRUITING
Phase	Phase 2
Sponsor	Implicit Bioscience
Enrollment	56 participants

Key Eligibility Criteria

Inclusion (9)

- Patients may be included in the study only if they meet all the following criteria:
 - Adult patients (18+) on mechanical ventilations with acute respiratory distress syndrome (ARDS) by Berlin Criteria (d48 hours)
 - P:F ratio \leq 300
 - Positive end-expiratory pressure (PEEP) \geq 5 cm H₂O
 - Bilateral opacities on chest x-ray or chest computerized tomography (CT)-- not fully explained by effusions, lobar/lung collapse, or nodules
- ... and 4 more (see full listing online)

Exclusion (26)

- An individual fulfilling any of the following criteria should be excluded from enrollment in the study:
 - Significant pre-existing organ dysfunction prior to hospitalization
 - Lung: Currently receiving home oxygen therapy as documented in medical record
 - Heart: Pre-existing congestive heart failure defined as an ejection fraction \leq 20% as documented in the medical record
 - Renal: End-stage renal disease requiring renal replacement therapy or estimated glomerular filtration rate (eGFR) \leq 30 mL/min.
- ... and 21 more (see full listing online)

Locations (2 total)

Harborview Medical Center, Seattle, Washington, United States
University of Washington, Seattle, Washington, United States